期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 291, 期 28, 页码 14747-14760出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M115.711515
关键词
cyclooxygenase (COX); prostaglandin; prostate; steroidogenesis; transforming growth factor (TGF-)
资金
- National Institutes of Health [5T32DK007774-15, R01GM086596]
Current pharmacotherapies for symptomatic benign prostatic hyperplasia (BPH), an androgen receptor-driven, inflammatory disorder affecting elderly men, include 5-reductase (5AR) inhibitors (i.e. dutasteride and finasteride) to block the conversion of testosterone to the more potent androgen receptor ligand dihydrotestosterone. Because dihydrotestosterone is the precursor for estrogen receptor (ER) ligands, 5AR inhibitors could potentially limit ER activation, which maintains prostate tissue homeostasis. We have uncovered signaling pathways in BPH-derived prostate epithelial cells (BPH-1) that are impacted by 5AR inhibition. The induction of apoptosis and repression of the cell adhesion protein E-cadherin by the 5AR inhibitor dutasteride requires both ER and TGF. Dutasteride also induces cyclooxygenase type 2 (COX-2), which functions in a negative feedback loop in TGF and ER signaling pathways as evidenced by the potentiation of apoptosis induced by dutasteride or finasteride upon pharmacological inhibition or shRNA-mediated ablation of COX-2. Concurrently, COX-2 positively impacts ER action through its effect on the expression of a number of steroidogenic enzymes in the ER ligand metabolic pathway. Therefore, effective combination pharmacotherapies, which have included non-steroidal anti-inflammatory drugs, must take into account biochemical pathways affected by 5AR inhibition and opposing effects of COX-2 on the tissue-protective action of ER.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据